America's Quiet War on International Science Collaboration

“Science has no borders” is one of those lines everyone nods at and nobody questions. In 2026, Washington is quietly questioning it. American researchers receiving federal funding now face mounting restrictions on publishing with foreign collaborators — a shift that isn’t just bureaucratic tightening. It may mark the end of the open-science model the US has championed for 80 years.

What’s actually happening

The mechanics are deceptively dry. Scientists holding federal grants increasingly need prior disclosure — and in some cases approval — before co-authoring with collaborators in flagged countries. The official rationale is technology leakage prevention, focused on so-called critical fields: AI, semiconductors, quantum computing, biotech. The worry is that decades of US advantage are quietly seeping out through joint papers and shared datasets.

The scope is what’s rattling labs. Until recently, these controls applied mainly to dual-use or defense-adjacent work. Now they’re creeping into basic research. As one tenured professor put it on a recent academic listserv: yesterday you co-wrote a paper with someone, today you think twice before emailing them.

The China Initiative’s afterlife

Remember the China Initiative? Launched in 2018, formally shuttered in 2022 after an embarrassing parade of dismissed cases and one high-profile acquittal of an MIT professor. Officially dead. In practice, its DNA has been spliced into new compliance regimes under different names.

This year, NSF and NIH dramatically expanded their “foreign affiliation disclosure” requirements. The reporting net now covers not just formal collaborations but conference talks, visiting positions, and reportedly even informal email exchanges. Penalties run from grant clawbacks to criminal exposure. The chilling effect is the point.

“Colder than the Cold War”

The pushback from inside US academia is sharper than you’d expect. AAAS, the National Academies, and most major scientific societies have issued increasingly pointed statements. The argument rests on two pillars.

First, American scientific dominance was built on openness. More than half of PhD students at MIT and Stanford are foreign-born. A staggering share of US Nobel laureates are immigrants. Closing the door is closing it on yourself.

Second, modern science literally cannot function this way. CERN’s particle physics runs on consortia spanning dozens of countries. Climate modeling pools data globally. mRNA vaccines moved at warp speed in 2020 because Chinese researchers published the SARS-CoV-2 genome in January, full stop. One molecular biologist noted that even at the height of the Cold War, American and Soviet scientists co-authored papers. The current moment is more closed than that.

The spillover beyond US borders

This isn’t a domestic US story. Researchers in Seoul, Tokyo, Berlin, and Tel Aviv are getting pulled in too. Korean universities and institutes are especially exposed — their strongest collaborations with American labs sit precisely in AI, semiconductors, and biotech, which is to say exactly the fields Washington is most paranoid about.

Three patterns are already visible. American co-authors are slow-walking data sharing, delaying joint publications. Korean postdocs landing in US labs are quietly excluded from the most sensitive projects. And industry-university tech transfer deals are being rewritten with far more restrictive IP language. Some Korean PIs report American collaborators asking to “leave that part out” before submission. Publishing a paper is starting to look like a diplomatic negotiation.

The world after decoupling

Zoom out and the trajectory is clearer: science itself is bifurcating into blocs. A US-led Western sphere and a China-centered counterpart, each with its own data infrastructure, talent pipelines, and publication ecosystems. China has been pouring resources into CNKI, its domestic academic database. Russia has effectively severed Western journal subscriptions since 2022.

The catch is that humanity’s hardest problems — pandemics, climate, food security — don’t respect blocs. COVID-19 vaccines arrived in record time partly because that January 2020 genome release happened at all. If that kind of reflexive sharing is over, what happens to the next outbreak?

Borderizing science may buy short-term security. Over a longer horizon it likely makes everyone poorer and more exposed. For countries caught in the middle — Korea among them — the right question isn’t whether to pick a side. It’s whether anyone wins the game being played.